Menu: Home :: go to Journal :: switch to Russian :: switch to English
You are here: all Journals and Issues→ Journal→ Issue→ Article

COLORECTAL CANCER IN TAMBOV PROVINCE: SOME ASPECTS OF EPIDEMIOLOGY

Annotation

A short review on colorectal cancer is made, some aspects of epidemiology are given in Tambov province. It is shown, that the sickness rate of colon cancer for 5 years is of undulating character, composing from 19 to 23.5 at 100 thousand of population. It is interesting that at the colon cancer the sickness for the same period has stable character, composing 17.3-17.4 %. At both localizations maximum peak of sickness is for 2012, composing 23.5 and 20 % accordingly. These rates are lower than middle Russian. One year lethality at colorectal cancer in Tambov province has tendency to the decrease. Thus, at colon cancer it was 28.6 % in 2009, and in 2014 - 20.9 %. At colon cancer these rates were 30.5 and 25.7 % accordingly. Standard rates of death at colorectal cancer are lower than in Russia and are of undulating character. But it is higher than at rectum cancer. This difference is due to anatomic features and efficiency of the treatment. The rates of undermaintenance at colorectal cancer in Tambov province are higher than in Russia, but they have stable tendency to decrease. Due to the implementation of modern methods of treatment 5 year survivability at colorectal cancer is always increasing, composing at colon cancer in 2014 42.7 % (in Russia - 50.2 %) and at rectum cancer - 53.5 % (in Russia - 49.6 %)

Keywords

colon cancer; rectum cancer; sickness rate; death; undermaintenance; analytical epidemiology

Full-text in one file

Download

UDC

616-006

Pages

1679-1684

References

1. Siegel R., Desantis C., Jemal A. Colorectal cancer statistics, 2014 // A Cancer Journal for Clinicians. 2014. V. 64 (2). P. 104-117. doi: 10. 3322/caac.21220. 2. World Health Organization Cancer Incidence in Five Continents. Lyon: The World Health Organization and the International Agency for Research on Cancer, 2002. 3. World Cancer Research Fund and American Institute for Cancer Re-search Food, Nutrition, Physical Activity, and the Prevention of Can-cer: A Global Perspective. Washington, DC: American Institute for Cancer Research, 2007. 4. Boyle P., Langman J.S. ABC of colorectal cancer: Epidemiology // BMJ. 2000. V. 321 (7264). P. 805-808. 5. Boyle P., Ferlay J. Mortality and survival in breast and colorectal cancer // Nat. Clin. Pract. Oncol. 2005. V. 2 (9). P. 424-425. 6. Parkin D., Bray F., Ferlay J. Global cancer statistics, 2002 // Cancer J. Clin. 2006. V. 55. P. 74-108. 7. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon: International Agency for Research on Cancer, 2004. 8. Janout V., Kollárová H. Epidemiology of colorectal cancer // Biomed. Pap. Med. Fac. Univ. Palacku Olomouc. Czech. Repub. 2001. V. 145. P. 5-10. 9. American Cancer Society Cancer Facts & Figures for African Ameri-cans 2009–2010. Oklahoma City, OK: American Cancer Society, 2009. Accessed May 26, 2009. 10. National Institutes of Health What You Need To Know About Cancer of the Colon and Rectum. Bethesda, MD: U.S. Department of Health and Human Services & National Institutes of Health, 2006. 11. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012: International Agency for research on Cancer. 12. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics // A Cancer Journal for Clinicians. 2014. V. 64 (1). P. 9-29. doi:10.3322/caac.21208. 13. Howlader N., Noone A.M., Krapcho M. et al. (eds). SEER Cancer Statistics Review, 1975–2011. Bethesda: National Cancer Institute, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission. 14. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2013 g. / pod red. A.D.Kaprina, V.V.Starinskogo, G.V. Petrovoy. M.: MNIOI im. P.A. Gertsena – filial FGBU «FMITs im. P.A. Ger-tsena» Minzdrava Rossii, 2014. 235 s. 15. Zlokachestvennye novoobrazovaniya v Rossii v 2013 g. (zabolevae-most' i smertnost') / pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoy. M.: MNIOI im. P.A. Gertsena – filial FGBU «FMITs im. P.A. Gertsena» Minzdrava Rossii, 2015. 250 s. 16. Jemal A., Clegg L.X., Ward E. et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival // Cancer. 2004. V. 101 (1). P. 3-27. 17. Labianca R., Beretta G.D., Mosconi S., Milesi L., Pessi M.A. Colorectal cancer: screening // Ann. Oncol. 2005. V. 16 (Suppl 2). P. 127-132. 18. de Jong A.E., Morreau H., Nagengast F.M. et al. Prevalence of adeno-mas among young individuals at average risk for colorectal cancer // Am. J. Gastroenterol. 2005. V. 100 (1). P. 139-143. 19. American Cancer Society. Colorectal Cancer Facts & Figures Special Edition 2005. Oklahoma City, OK: American Cancer Society, 2005. Accessed May 26, 2009. 20. Davies R.J., Miller R., Coleman N. Colorectal cancer screening: pros-pects for molecular stool analysis // Nat. Rev. Cancer. 2005. V. 5. P. 199-209. 21. Grande M., Milito G., Attina G.M. et al. Evaluation of clinical, laboratory and morphologic prognostic factors in colon cancer // World J. Surg. Oncol. 2008. V. 6. P. 98. 22. Skibber J., Minsky B., Hoff P. // De Vita V.T. Jr., Hellmann S., Rosen-berg S.A., editor. Cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001. Cancer of the colon and rectum. P. 1216-1271. 23. Boardman L.A., Morlan B.W., Rabe K.G. et al. Colorectal cancer risks in relatives of young-onset cases: is risk the same across all first-degree relatives? // Clin. Gastroenterol. Hepatol. 2007. V. 5 (10). P. 1195-1198. 24. Wilmink A.B.M. Overview of the epidemiology of colorectal cancer // Dis. Colon Rectum. 1997. V. 40 (4). P. 483-493. 25. Jackson-Thompson J., Ahmed F., German R.R., Lai S.M., Friedman C. Descriptive epidemiology of colorectal cancer in the United States, 1998–2001 // Cancer. 2006. V. 107. Suppl 5. P. 1103-1111. 26. Jeter J.M., Kohlmann W., Gruber S.B. Genetics of colorectal cancer // Oncology. 2006. V. 20 (3). P. 269-276. 27. Al-Sukhni W., Aronson M., Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome // Surg. Clin. North Am. 2008. V. 88 (4). P. 819-844. 28. Johnson I.T., Lund E.K. Review article: nutrition, obesity and colorec-tal cancer // Aliment. Pharmacol. Ther. 2007. V. 26 (2). P. 161-181. 29. Larsson S.C., Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies // Int. J. Cancer. 2006. V. 119 (11). P. 2657-2664. 30. Santarelli R.L., Pierre F., Corpet D.E. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence // Nutr. Cancer. 2008. V. 60 (2). P. 131-144. 31. Willett W.C. Diet and cancer: an evolving picture // JAMA. 2005. V. 293 (2). P. 233-234. 32. Ries L.A.G., Melbert D., Krapcho M. et al. SEER cancer statistics review, 1975–2005. Bethesda, 2008. 33. Fazeli M.S., Keramati M.R. Rectal cancer: a review // Med. J. Islam Repub. Iran. 2015 (31 January). V. 29. P. 171. 34. Fairley T.L., Cardinez C.J., Martin J. et al. Colorectal cancer in U.S. adults younger than 50 years of age, 1998–2001 // Cancer. 2006. V. 107. Suppl 5. P. 1153-1161. 35. O'Connell J.B., Maggard M.A., Liu J.H. et al. Rates of colon and rectal cancers are increasing in young adults // Am. Surg. 2003. V. 2003 (69). P. 866-872. 36. O'Connell J.B., Maggard M.A., Livingston E.H., Yo C.K. Colorectal cancer in the young // Am. J. Surg. 2004. P. 187 (3). P. 343-348. 37. Yamauchi M., Morikawa T., Kuchiba A. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum // Gut. 2012. V. 61 (6). P. 847-854. 38. Adam R., Haller D.G., Poston G. et al. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the international congress on anti-cancer treatment (ICACT) 2009 // Annals of Oncology. 2010. V. 21 (8). P. 1579-1584. 39. Hemminki K., Santi I., Weires M., Thomsen H., Sundquist J., Ber- mejo J.L. Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes // BMC Cancer. 2010. V. 10. P. 688. 40. Weiss J.M., Pfau P.R., O'Connor E.S. et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data // Journal of Clinical Oncology. 2011. V. 29. P. 4401-4409. 41. Ogino S., Chan A.T., Fuchs C.S., Giovannucci E. Molecular pathologi-cal epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field // Gut. 2011. V. 60 (3). P. 397-411. 42. Gervaz P., Bucher P., Morel P. Two colons-two cancers: paradigm shift and clinical implications // Journal of Surgical Oncology. 2004. V. 88 (4). P. 261-266. 43. Chauvenet M., Cottet V., Lepage C., Jooste V., Faivre J., Bouvier A.M. Trends in colorectal cancer incidence: a period and birth-cohort analy-sis in a well-defined French population // BMC Cancer. 2011. V. 11. P. 282. 44. Larsen I.K., Bray F. Trends in colorectal cancer incidence in Norway 1962–2006: an interpretation of the temporal patterns by anatomic subsite // International Journal of Cancer. 2010. V. 126 (3). P. 721-732. 45. Shah A.B., Sarfati D., Blakely T., Atkinson J., Dennett E.R. Trends in colorectal cancer incidence rates in New Zealand, 1981–2004 // ANZ Journal of Surgery. 2012. V. 82. P. 258-264. 46. Derwinger K., Gustavsson B. Variations in demography and prognosis by colon cancer location // Anticancer Research. 2011. V. 31 (6). P. 2347-2350. 47. Lagergren J., Ye W., Ekbom A. Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? // Gastroenterology. 2001. V. 121 (3). P. 542-547. 48. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies // The Lancet. 2008. V. 371 (9612). P. 569-578. 49. Wong V.W.S., Wong G.L.H., Tsang S.W.C. et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis // Gut. 2011. V. 60 (6). P. 829-836. 50. Sjo O.H., Berg M., Merok M.A. et al. Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors // Journal of Surgical Oncology. 2011. V. 104 (7). P. 792-797. 51. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO Classification of Tumours of the Digestive System. 4th edition. Lyon: WHO Press, 2010. 52. Verhulst J., Ferdinande L., Demetter P., Ceelen W. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis // Journal of Clinical Pathology. 2012. V. 65 (5). P. 381-388. 53. Catalano V., Loupakis F., Graziano F. et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy // British Journal of Cancer. 2009. V. 100 (6). P. 881-887. 54. Vaughn C.P., Zobell S.D., Furtado L.V., Baker C.L., Samowitz W.S. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer // Genes Chromosomes and Cancer. 2011. V. 50 (5). P. 307-312. 55. Bokemeyer C., Cutsem E.V., Rougier P. et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials // European Journal of Cancer. 2012. V. 48 (10). P. 1466-1475. 56. Yokota T., Ura T., Shibata N. et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer // British Journal of Cancer. 2011. V. 104 (5). P. 856-862. 57. Di Nicolantonio F., Martini M., Molinari F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer // Journal of Clinical Oncology. 2008. V. 26 (35). P. 5705-5712. 58. Laurent-Puig P., Cayre A., Manceau G. et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab thera-py in wild-type KRAS metastatic colon cancer // Journal of Clinical Oncology. 2009. V. 27 (35). P. 5924-5930. 59. Maughan T.S., Adams R.A., Smith C.G. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial // The Lancet. 2011. V. 377 (9783). P. 2103-2114. 60. Ogino S., Shima K., Meyerhardt J.A. et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from inter-group trial CALGB, 89803 // Clinical Cancer Research. 2012. V. 18. P. 890-900. 61. World Health Organization. 2014 [cited 20145/13/2014]. Available from.

Received

2015-08-07

Section of issue

Medicine

Для корректной работы сайта используйте один из современных браузеров. Например, Firefox 55, Chrome 60 или более новые.